Alkem Laboratories Limited

NSEI:ALKEM Stock Report

Market Cap: ₹648.9b

Alkem Laboratories Valuation

Is ALKEM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ALKEM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ALKEM (₹5427.5) is trading above our estimate of fair value (₹2733.04)

Significantly Below Fair Value: ALKEM is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ALKEM?

Key metric: As ALKEM is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for ALKEM. This is calculated by dividing ALKEM's market cap by their current earnings.
What is ALKEM's PE Ratio?
PE Ratio30.6x
Earnings₹21.22b
Market Cap₹648.94b

Price to Earnings Ratio vs Peers

How does ALKEM's PE Ratio compare to its peers?

The above table shows the PE ratio for ALKEM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average31.9x
500488 Abbott India
47.4x10.9%₹608.5b
AUROPHARMA Aurobindo Pharma
20.1x13.9%₹721.2b
500257 Lupin
37.3x16.4%₹979.7b
ZYDUSLIFE Zydus Lifesciences
22.9x0.7%₹979.6b
ALKEM Alkem Laboratories
30.6x10.6%₹648.9b

Price-To-Earnings vs Peers: ALKEM is good value based on its Price-To-Earnings Ratio (30.6x) compared to the peer average (31.9x).

Price to Earnings Ratio vs Industry

How does ALKEM's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
INDSWFTLAB Ind-Swift Laboratories
1.7xn/aUS$74.49m
524652 Ind-Swift
2.9xn/aUS$18.48m
No more companies available in this PE range
ALKEM 30.6xIndustry Avg. 33.6xNo. of Companies17PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: ALKEM is good value based on its Price-To-Earnings Ratio (30.6x) compared to the Indian Pharmaceuticals industry average (33.6x).

Price to Earnings Ratio vs Fair Ratio

What is ALKEM's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ALKEM PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio30.6x
Fair PE Ratio40.1x

Price-To-Earnings vs Fair Ratio: ALKEM is good value based on its Price-To-Earnings Ratio (30.6x) compared to the estimated Fair Price-To-Earnings Ratio (40.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ALKEM forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹5,427.50
₹5,775.29
+6.4%
13.0%₹7,225.00₹4,330.00n/a21
Dec ’25₹5,642.45
₹5,775.29
+2.4%
13.0%₹7,225.00₹4,330.00n/a21
Nov ’25₹5,805.25
₹5,721.90
-1.4%
14.5%₹7,225.00₹3,960.00n/a21
Oct ’25₹6,151.25
₹5,583.24
-9.2%
14.3%₹6,833.00₹3,960.00n/a21
Sep ’25₹6,170.35
₹5,543.95
-10.2%
13.6%₹6,833.00₹3,960.00n/a21
Aug ’25₹5,271.30
₹5,213.19
-1.1%
14.0%₹6,891.00₹3,600.00n/a21
Jul ’25₹4,958.60
₹5,194.86
+4.8%
14.1%₹6,891.00₹3,600.00n/a21
Jun ’25₹4,810.45
₹5,152.18
+7.1%
14.1%₹6,891.00₹3,600.00n/a22
May ’25₹4,833.05
₹5,235.45
+8.3%
13.8%₹6,780.00₹3,600.00n/a22
Apr ’25₹5,009.05
₹5,222.95
+4.3%
14.0%₹6,780.00₹3,600.00n/a22
Mar ’25₹5,112.90
₹5,234.32
+2.4%
14.1%₹6,780.00₹3,600.00n/a22
Feb ’25₹4,854.75
₹4,299.74
-11.4%
15.3%₹6,295.00₹2,700.00n/a23
Jan ’25₹5,120.00
₹4,131.26
-19.3%
17.0%₹6,295.00₹2,700.00n/a23
Dec ’24₹4,647.90
₹4,032.91
-13.2%
13.4%₹4,980.00₹2,700.00₹5,642.4522
Nov ’24₹3,722.65
₹3,681.00
-1.1%
11.0%₹4,850.00₹2,700.00₹5,805.2522
Oct ’24₹3,605.90
₹3,690.81
+2.4%
13.0%₹4,850.00₹2,685.00₹6,151.2521
Sep ’24₹3,614.75
₹3,673.05
+1.6%
13.0%₹4,850.00₹2,685.00₹6,170.3522
Aug ’24₹3,986.50
₹3,359.41
-15.7%
13.0%₹4,350.00₹2,685.00₹5,271.3022
Jul ’24₹3,512.85
₹3,314.68
-5.6%
11.1%₹3,900.00₹2,685.00₹4,958.6022
Jun ’24₹3,380.35
₹3,310.36
-2.1%
11.0%₹3,900.00₹2,685.00₹4,810.4522
May ’24₹3,509.90
₹3,394.52
-3.3%
12.6%₹4,100.00₹2,600.00₹4,833.0521
Apr ’24₹3,396.10
₹3,375.00
-0.6%
11.9%₹3,900.00₹2,600.00₹5,009.0521
Mar ’24₹3,119.20
₹3,375.00
+8.2%
11.9%₹3,900.00₹2,600.00₹5,112.9021
Feb ’24₹3,030.45
₹3,211.81
+6.0%
12.4%₹3,795.00₹2,475.00₹4,854.7521
Jan ’24₹3,004.70
₹3,237.14
+7.7%
11.9%₹3,795.00₹2,475.00₹5,120.0021
Dec ’23₹3,130.10
₹3,239.04
+3.5%
11.4%₹3,795.00₹2,475.00₹4,647.9023

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 21:02
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Alkem Laboratories Limited is covered by 35 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Prashant NairAmbit Capital
Shrikant AkolkarAngel Broking Private Limited
null nullAntique Stockbroking Ltd.